研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co.,Ltd.[2]The Second People's Hospital of Shenzhen Shenzhen,Guangdong,China,518035[3]Affiliated Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology Wuhan,Hubei,China,430030[4]Affiliated Zhongshan Hospital of Fudan University Shanghai,Shanghai,China,200032[5]The First Affiliated Hospital,Medical College,Zhejiang University Hangzhou,Zhejiang,China,310013
研究目的：
The purpose of this multicenter,open, prospective and single arm study is to evaluate the efficacy and safety of domestic dasatinib in the first-line treatment of newly diagnosed CML-CP
